The convergence of socioeconomic and technology factors – the growing emphasis on drug self-administration for chronic conditions, the expected acceleration in protein- and peptide-based therapeutics, the availability of innovative dry powder inhalation devices with unique device designs - is driving interest in pulmonary drug delivery technology and devices as an alternative to oral and parenteral routes of administration. While several approaches for delivering active substances to, and systematically via, the lungs compete in this space, recent advances and investment in powder formulations, particle engineering, and device architecture have positioned dry powder inhalers to take full advantage of these trends. The report includes comprehensive assessments of current and future dry powder inhalation, dry powder inhalation technology, industry data and forecasts, device and particle technology profiles, key alliances and partnerships, and detailed analysis of design and economic factors. The report has been organized and written to provide pharmaceutical professionals, drug delivery market participants, and supply chain companies with all of the information necessary to understand the growing impact of dry powder inhalers on drug design and development,  therapeutic protocols, and healthcare economics.

Publication Date: May 2008